Advanced malignancy

Kazia closes oversubscribed offering to fund paxalisib’s clinical development

Kazia Therapeutics has closed an oversubscribed public offering that could provide the company with up to $120m in gross proceeds if all milestone-linked warrants are exercised, aimed primarily at funding clinical development of paxalisib.

Jazz secures FDA approval for Ziihera in advanced HER2+ GEA

The US Food and Drug Administration (FDA) has approved two Jazz Pharmaceuticals regimens containing Ziihera (zanidatamab-hrii) for the first-line treatment of adults with unresectable, locally advanced or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastroesophageal adenocarcinoma (GEA).

BMS secures FDA accelerated approval for Zenbexus in multiple myeloma

The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s (BMS) Zenbexus (iberdomide), along with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd), to treat adult multiple myeloma (MM) patients.

Akeso secures China NMPA authorisation for ivonescimab combo

Summit Therapeutics’ partner Akeso has secured China’s National Medical Products Administration (NMPA) authorisation for the use of ivonescimab in combination with chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer (NSCLC) patients.

BeOne and Revolution Medicines partner for oncology therapies

BeOne Medicines has signed a multi-part collaboration with Revolution Medicines to develop and commercialise targeted oncology therapies.

FDA grants breakthrough therapy designation to Lilly’s olomorasib

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Eli Lilly and Company’s (Lilly) olomorasib as a potential treatment for adults with advanced pancreatic cancer who have already received at least one prior systemic therapy.

Ratio Therapeutics secures $70m Series C funding for cancer radiotherapy

Ratio Therapeutics, a US-based clinical-stage developer of radiopharmaceuticals for cancer treatment, has closed a $70m Series C financing round.